Allo-HSCT in transplant-naive patients with Hodgkin lymphoma: a single-arm, multicenter study.
Ontology highlight
ABSTRACT: We evaluated the role of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in transplant-naïve patients with relapsed/refractory Hodgkin lymphoma (HL) who failed to attain metabolic complete response (mCR) to 1 to 2 lines of salvage chemotherapyThose with residual but nonprogressive disease assessed by positron emission tomography/computed tomography scanning were eligible. An additional 1 to 2 cycles of salvage therapy were permissible in those with progressive disease or when required to bridge to allo-HSCT, with additional imaging at baseline before transplantation. Conditioning consisted of carmustine, etoposide, cytarabine, melphalan, and alemtuzumab. Donor lymphocyte infusions (DLI) were administered for mixed chimerism or residual or relapsed disease. Eleven patients ha
SUBMITTER: Das-Gupta E
PROVIDER: S-EPMC6929392 | biostudies-literature | 2019 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA